CX-011 / CarthroniX - LARVOL DELTA

Evaluation of Intra-articular CX-011 to Treat Moderate to Severe Pain From Knee Osteoarthritis (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: CarthroniX, Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Feb 2026 ➔ Aug 2026

Enrollment open • Trial initiation date • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology • CRP

Evaluation of Intra-articular CX-011 to Treat Moderate to Severe Pain From Knee Osteoarthritis (clinicaltrials.gov) - P1/2 | N=72 | Not yet recruiting | Sponsor: CarthroniX, Inc.

New P1/2 trial • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Novel Small Molecule Modulator of the gp130 Receptor Shows Dose-dependent Therapeutic Efficacy in a Canine Model of Osteoarthritis (ACR Convergence 2022) - "Taken together, these data suggest efficacy in controlling joint disease progression and its symptoms as well as a good safety profile for CX-011. We have shown that the high 10 μg and medium 1 μg dose groups prevent some of the most important pathophysiological changes promoting osteoarthritis progression. Notably, bone remodeling and shape change is prevented."

Clinical • Preclinical • Anesthesia • Immunology • Inflammation • Orthopedics • Osteoarthritis • Pain • Rheumatology • IL6